Blockchain Registration Transaction Record

GeoVax's GEO-MVA Aims to Combat Global Mpox Threat with Scalable Vaccine

GeoVax Labs develops GEO-MVA, a scalable Mpox vaccine, to address global supply shortages and combat the spread of the virulent Clade 1 strain, enhancing pandemic preparedness.

The development of GEO-MVA by GeoVax Labs is crucial in addressing the global shortage of Mpox vaccines and reducing dependence on a single supplier, which currently limits the world's ability to respond effectively to outbreaks. This initiative not only enhances pandemic preparedness but also ensures more equitable access to vaccines, particularly in regions most affected by the virus. The advancement of GEO-MVA could significantly impact public health strategies by providing a scalable and cost-effective solution to combat the spread of Mpox, especially the virulent Clade 1 strain, thereby safeguarding communities worldwide.